Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
13.20
+0.16 (1.23%)
At close: Apr 28, 2026, 4:00 PM EDT
13.04
-0.16 (-1.21%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 377 employees as of December 31, 2025. The number of employees decreased by 26 or -6.45% compared to the previous year.
Employees
377
Change (1Y)
-26
Growth (1Y)
-6.45%
Revenue / Employee
$179,499
Profits / Employee
-$1,094,679
Market Cap
1.56B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 711 |
| Ardelyx | 489 |
| Vir Biotechnology | 367 |
| Nuvation Bio | 298 |
| Monte Rosa Therapeutics | 150 |
| Nanobiotix | 103 |
| AtaiBeckley | 99 |
| Rapport Therapeutics | 84 |
NTLA News
- 1 day ago - Intellia Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 1 day ago - Intellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test - Benzinga
- 1 day ago - Intellia Therapeutics Transcript: Study result - Transcripts
- 1 day ago - Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial - Reuters
- 1 day ago - Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial - CNBC
- 1 day ago - Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema - GlobeNewsWire
- 1 day ago - Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing - GlobeNewsWire
- 4 days ago - Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 - GlobeNewsWire